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Cervical cancer is the most frequent cancer found in Indonesia. The primary 
treatment of cervical cancer at the locally advanced stage is usually performed by 
using radiotherapy and chemotherapy. The combination of the two techniques is 
often called chemoradioherapy. The response to chemoradiotherapy is influenced by 
biological and physical factors. Major vault protein (MVP) is a ribonucleoprotein 
which contributes to drug resistance in some cancers. The purposes of this research 
were: (1) to determine the correlation between the expression of MVP and the index 
of p53, including AgNOR values and index of MIB-1; and (2) between MVP and 
chemoradiotherapy clinical response of cervical cancer. Twenty-one microscopic 
slides taken from biopsy tissues of cervical cancer patients before undergoing 
treatment were stained to identify MVP, p53, and MIB-1 by means of 
immunohistochemistry techniques and AgNORs staining. After undergoing 
chemoradiotherapy treatment, the patients’ clinical responses were observed by 
pelvic control method. Experimental results showed that there was a correlation 
between MVP and AgNOR value (P=0.05), but no correlation between MVP and 
index of p53 (P=0.729), including MIB-1 LI (P=0.63), in untreated cervical cancer. 
In addition, there was no association between MVP and chemoradioterapy response. 
In conclusion, MVP expression correlates with the process of cell proliferation 
before the G2 phase of cell cycle in untreated cancer cells. Those have no 
association with clinical responses after the completion of treatment. 
 
 
© 2014 Atom Indonesia. All rights reserved 
 
 
INTRODUCTION 
 
Carcinoma cervix uterine is the second most 
common malignant tumor in women worldwide, 
with an estimated 493,000 new cases (83% 
occurring in developing countries) and 274,000 
cancer-related deaths in the year 2002 [1].                 
In Indonesia, this is the most common cancer type 
and 70% of the patients came to hospital in locally 
advanced stage condition. The main treatment              
for this stage is radiotherapy combined with 
chemotherapy in concurrent chemoradiotherapy 
[2,3]. Establishing the prognosis of a patient with 
cervical cancer is an important part of the clinical 
evaluation and treatment. The most recognized 
prognostic factor in cervical cancer is the disease 
extension, usually estimated by the TNM/FIGO 
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staging system (Tumor-Nodus-Metastasis / Interna-
tional Federation of Gynecology and Obstetrics)      
[4-6]. However, within each clinical disease stage, 
biological markers are needed to clarify the 
identification of high risk patients who may benefit 
from individualized therapeutic options of 
carcinoma cervix uterine [7]. 
The vault is a barrel-shaped cytoplasmic 
riboprotein particle which is grouped into multiple 
copies of three proteins. The mammalian vault 
complex is made of major vault protein or                 
lung resistance-related protein (MVP or LRP,        
M(r) = 100,000), vault poly ADP-ribose polymerase 
(VPARP, M(r) 193,000) and telomerase associated 
protein 1 (TEP-1, M(r) = 240,000) which are 
associated with small 88-141-bp fragments of 
untranslated RNA [8-11]. While vaults are found in 
all human tissues, elevated level of expression of 
MVP is found in gut epithelium, lung epithelium, 
macrophages and dendritic cells, which are all 
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typically exposed to xenobiotics. This implies that 
vaults may have a role in the defense of such tissue 
against toxic insult, and they are found highly 
expressed in various multidrug-resistant cancer cell 
lines [12-14]. 
Growing cancers are often influenced by 
increased genetic changes. Such genetic changes, 
including chromosomal aberrations (translocations), 
gene amplifications, intragenic mutations, and gene 
silencing are responsible for the activation of 
oncogenes and the inactivation of tumor-suppressor 
genes. Exposure of cells to extreme conditions like 
cancer cell hypoxia can promote genome alterations, 
enhancing the progression potential of tumor cells 
and resistance to oncological treatments. Hypoxia 
may lead to conditions that cause increased damage 
to DNA or inhibit DNA repair processes, impair 
DNA and cause tumor progression by altering p53 
expressions and increasing angiogenesis. Loss of 
regulation of DNA repair pathways can influence 
the phenomenon of hypoxia-induced genetic 
instability within the tumor [15-18]. 
The MIB-1, also called Ki-67, is expressed in 
all cell cycle stages except G0 and early G1 phases. 
This antigen is thought to be associated with a 
nuclear antigen protein-DNA replicase complex, 
similar to DNA topoisomerase II [19]. Generally, a 
higher MIB-1 labeling index (MIB-LI / MIB-1 LI) 
correlates with worse prognosis; however, tumors 
with higher MIB-1 LI are often radiosensitive [20]. 
Nucleolar organizer regions (NORs) are 
chromosomal loops of DNA involved in ribosomal 
synthesis. The silver staining technique can easily 
detect NORs in formalin fixation, and NORs can be 
identified as black dots in the nucleolus (AgNORs). 
This method permits the rapid evaluation of 
morphology and tumor cell kinetics even using 
small biopsies. Evaluation of AgNOR parameters 
(number, size, and distribution) has been applied in 
tumor pathology both for diagnostic and prognostic 
purposes [21, 22]. 
In the last few years a considerable number of 
studies have shown correlation between biomarkers 
of cell proliferation - such as index of p53, index of 
MIB-1, and AgNORs - and chemoradiotherapy or 
radiotherapy clinical responses [20,23,24]. While 
there a positive correlation between AgNORs           
and MIB-1, AgNOR value tends to decrease 
whereas the index of MIB-1 increases if cervical 
cancer is treated specially for one week with 
chemoradiotherapy [24]. 
The aim of the present study was to assess (1) 
the correlation between the expression of the MVP 
in chemoradiotherapy untreated cervical cancer and 
AgNOR values, including also index of MIB-1 and 
index of p53, and (2) the correlation between MVP 
and clinical response of cervical cancer to 
chemoradiotherapy. 
 
 
EXPERIMENTAL METHODS 
 
Patients 
 
From July 2010 to March 2011, 21 
consecutive patients were enrolled and studied in 
this work. Their data is summarized in Table 1. 
Those patients were taken from a whole series of      
60 cases who were suffering from non-metastatic 
localized cervical carcinoma in stage IIB-IIIB. 
Among those 60 patients, the 21 patients studied 
were the ones who have achieved complete response 
to treatment. All patients were diagnosed and treated 
by definitive radiation at the Cipto Mangunkusumo 
Hospital and Hasan Sadikin Hospital and received 
written informed consent. The study was approved 
by the Health Research Ethics Committee               
of the Faculty of Medicine, University of Indonesia.  
 
Table 1. Expression of Major Vault Protein (MVP), index of 
p53, index of MIB-1 , value of AgNORs and clinical response 
in cervical cancer treated with chemoradiotherapy 
 
No Patient 
Clinal 
Stage 
MVP Index 
of 
p53 
MIB-
1LI 
AgNORs 
Value 
Chemoradiotherapy 
Expre 
ssion 
Grouped Response Grouped 
1 A IIB W 1 0,21 0,40 5,71 partial 1 
2 B IIB W 1 0,36 0,43 6,38 partial 1 
3 C IIIB W 1 0,36 0,38 6,46 partial 1 
4 D IIB M 2 0,36 0,51 5,15 partial 1 
5 E IIIB M 2 0,17 0,30 4,41 complete 2 
6 F IIB M 2 0,26 0,29 5,03 complete 2 
7 G IIB S 2 0,48 0,59 5,26 complete 2 
8 H IIIA M 2 0,67 0,67 7,59 complete 2 
9 I IIIB S 2 0,65 0,36 4,24 complete 2 
10 J IIIB M 2 0,38 0,31 5,79 complete 2 
11 K IIIB M 2 0,60 0,21 4,66 partial 1 
12 L IIB M 2 0,36 0,41 5,24 partial 1 
13 M IIIB M 2 0,59 0,41 4,52 complete 2 
14 N IIB M 2 0,28 0,68 5,38 partial 1 
15 O IIB W 1 0,66 0,60 4,76 complete 2 
16 P IIB M 2 0,48 0,50 6,67 complete 2 
17 Q IIB M 2 0,54 0,31 5,93 complete 2 
18 R IIB M 2 0,44 0,55 4,77 complete 2 
19 S IIB M 2 0,43 0,47 5,53 complete 2 
20 T IIB W 1 0,39 0,52 8,65 complete 2 
21 U IIB S 2 0,13 0,36 5,22 complete 2 
Note : w = weak, m = medium s = strong 
 
The clinical staging of the patients was performed 
through speculoscopy, bimanual examination, and 
cystoscopy or rectoscopy when abdomen pelvic CT 
scans and chest X-rays were performed. The 
histological grading was based on the guidance 
issued by the Union for International Cancer 
Control [3] which defined the following grades: G1, 
well differentiated; G2, moderately differentiated; 
and G3, poorly differentiated or undifferentiated. 
All patients were identified as having squamous cell 
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carcinoma tumors, i.e., 14 patients in stage IIB, 1 
patient in stage IIIA and 6 patients in stage IIIB, 
respectively. 
 
 
Treatment 
 
Patients were treated by means of a 
combination of External Beam Radiotherapy 
(EBRT) with 
60
Co gamma rays and High Dose-Rate 
Intracavitary Brachytherapy (HDR-ICBT) using 
192
Ir. EBRT was subjected to the whole pelvis with a 
clinical target volume that included the primary 
cancer, uterus, internal iliac, presacral, upper 
external iliac, and lower common iliac lymph 
nodes.Chemotherapy was administered concurrently. 
Cisplatin was given before EBRT within two hours 
or less before treatment [25-27]. 
 
 
Clinical radiotherapy response 
 
Radiation responses were evaluated by 
radiotherapist in the Department of Radiotherapy, 
Cipto Mangunkusumo or Hasan Sadikin Hospital, 
and the responses are grouped according to               
Hong Criteria [28] as follows: (i) NRT (no gross 
residual tumor) response; complete or nearly 
complete regression of pelvic tumor, nonspecific 
fibrosis, or granulation over the cervix.                
This is called good response. (ii) GT (gross    
residual tumor) response: gross tumor or            
palpable nodularity on cervix, and/or palpable in 
duration on the parametrium. This is called                
bad response. 
 
 
Immunohistochemistry 
 
Expressions of MVP, p53, and MIB-1 were 
examined by immunohistochemistry. In brief,              
the steps were as follows: paraffin-embedded      
tumor tissue biopsies were first incubated with 
mouse anti-MVP monoclonal antibody (LRP/MVP 
Ab-2,  Clon 1032, Abcam, CA); then applied               
at a 1:100 dilution, anti p53 monoclonal               
antibody (Leica, Novocastra, ready-to-use p53-
D07); the biopsies were then incubated overnight at 
5°C, in a moist chamber; followed with                 
post primary, post protein and Novolink HRP 
system (Novolink) and revealed with DAB 
(Novolink) and counterstained with Mayer 
Hematoxylin. The primary antibody was omitted  
in one section as a negative control and a             
strongly positive tumor for MVP was used                     
as a positive control. Expressions of MVP                    
in cell cytoplasm and membrane was observed               
in zones of maximum expression of the marker            
in at least 10 high power fields (400×) and                   
semi quantitatively scored as low (negative/slightly 
positive) or high (strongly positive) [29,30].    
Staining for p53, observed in the nuclei, was  
scored as percentage of stained cells [24].                
Up to 1000 cells were counted in each slide              
of patient. 
 
 
AgNOR staining 
 
AgNOR staining technique was performed  
in accordance with the technique described by 
Ploton et al. [31,32]. Tissue sections were cut              
at 4 μm thickness from formalin fixed, paraffin-wax 
embedded blocks. The sections were dewaxed           
in xylene and then hydrated through decreasing 
grades of ethanol followed by washing in deionized 
water for 8–10 minutes. The staining solution           
was prepared by dissolution of powdered              
gelatin with concentration of 2% w/v in deionized 
water over water bath at 60–70°C. Pure formic  
acid was added to final concentration of 1%.                
This solution was mixed 1:2 (v/v) with 50% 
aqueous silver nitrate solution, then filtered         
through a 0.22 mm Millipore filter, and                
dropped onto the slide-mounted section.                 
The sections were incubated in the dark for 40–45 
minutes at room temperature. After rinsing               
three times with deionized water, the slides            
were immersed for 10 minutes in 5% sodium 
thiosulphate solution, dehydrated in ascending 
ethanol concentrations, cleared with xylene,               
and mounted. According to the recommendations  
of Crocker et al. [32], dots lying in a group            
or cluster (almost aggregated or partly 
disaggregated) were treated as one structure, 
whereas if AgNORs could been seen separately they               
were considered as individual AgNORs [33]. 
 
 
Statistical analysis 
 
AgNOR values, indices of p53, and indices of 
MIB-1 were analyzed by using Kolmogorov test  
for categorized normal distribution. Analysis           
of variance (ANOVA) was used to analyze                 
the correlation between the expression level              
of MVP in cancer with biomarkers of cell 
proliferation, i.e., AgNOR value, index of p53, and 
index of MIB-1. Fisher’s Exact Test was used to 
analyses association between MVP expression and 
chemoradiotherapy clinical response. All statistical 
analyses were performed using Medcalc Software       
Version 9.2.0.1. 
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RESULTS AND DISCUSSION 
 
All immunohistochemical markers and 
AgNOR staining were obtained in all 21 
microscopic slide from 21 cases (Table 1).                  
It appears that the expression of MVP in cancer   
cell cytoplasm was shown as brown color                 
(Fig. 1a,b,c). Based on MVP expressions, Table 1 
classifies patients into two groups. Group 1 consists 
of 5 patients (18.5%) who have low MVP 
expression, while the 16 patients (81.5%)                  
with strong or medium MVP expression for                  
16 patients are categorized as Group 2. Table 1   
also indicates that 4 of 14 patient (29 percent) in 
clinical stage IIB show low expression of MVP, 
while in IIIA and IIIB stages, the same low 
expression is indicated by 1 of 7 patients (14%).   
In the same table, it appears that the AgNOR value 
in stage IIB is 5.69 while in stages IIIA and IIIB it is 
5.38. The expression of p53 protein in nuclei as 
brown color is shown in Fig. 2a and indices of          
p53 with the values varying from 13% to 67% 
(mean 41%) is presented in Table 1. 
 
 
(a) 
 
 
(c) 
 
(b) 
 
 
(d) 
 
Fig. 1. Expression of MVP (a) weak, (b) medium, and        
(c) strong, in cervical cancer tissues before treatment by 
chemoradiotherapy,  negative control from breast cancer tissue 
(d), originally magnification 10 x 40. 
 
 AgNORs in nuclei result in a dot and group of 
dots with black color (see Fig. 2b), and MIB-1 
expression in nucleus as brown color one is depicted 
in Fig. 2c. AgNOR scores varied from 4.24 to 8.65 
(mean 5.59 ± 1.09) and MIB-1 indices varied from 
0.21–0.68  0.13 (see Table 1). We observed 
statistical correlation between the expression of 
MVP and AgNORs, P = 0.05 ( see Fig. 3b). There 
was no statistical correlation between expression of 
MVP and the index of p53 with P = 0.72>0.05      
(see Fig. 3a), and between MVP expression                
and MIB-1 index with P=0.63 (see Fig. 3c). Further, 
there was no correlation between MVP expression 
and chemoradiotherapy clinical response, as                
P = 0.28>0.05 (see Fig. 3d). 
 
 
(a) 
 
(b) 
 
 
(c) 
 
Fig. 2. Expression of (a) p53, (b) AgNORs, and (c) MIB-1 in 
cervical cancer tissue before treatment by chemoradioterapy, 
originally magnification10 x 40. 
 
 
  (a) 
 
  (c) 
(b) 
 
 
 
(d) 
 
Fig. 3. (a) Index of p53 in low and strong MVP, (b) Value of 
AgNOR in low and strong MVP, (c) Index of MIB-1 in low   
and strong MVP, and (d) expression of MVP grouped 
chemoradiotherapy clinical response. 
 
Theoretically, any relationship between MVP 
and AgNORs may be associated with degradation of 
nucleolin as part protein of AgNORs in preparing 
proliferation processes in the S phase before a cell 
enters the mitotic phase. An increase in AgNORs 
volume would indicate transcriptional activation of 
inactive NORs, and a reduction in number of 
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AgNORs in nucleus may indicate association 
processes. However, the decreases of the number of 
AgNORs and increases in its volume could not be 
explained by association processes alone, but it also 
results from an absolute rise in transcriptional 
activity [22,24]. In contrast to AgNOR values, MIB-
1 indices were found in all phases of cell cycle 
except in G0 phase (phase before entering into 
mitosis) [20], but it had no correlation with MVP 
expressions. This means that the expression of MVP 
is not related with the cancer cell proliferation 
process. 
The same is indicated by the expression of 
p53 that is not correlated with MVP. The p53 is a 
protein expressed in the tumor suppressor gene; it 
functions in cell cycle arrest if any DNA damage is 
found, and in initiating apoptosis. In this way, 
protein p53 initiates the formation of protein Bax, 
and also has a role in preventing apoptosis from 
inducing the activation of Bcl-2 protein [17,18]. The 
poor prognosis after radiotherapy is related with the 
failure of the processes of apoptosis and hypoxia. 
MVP and vaults have recently been linked to both 
major DNA double-strand break repair machineries, 
namely Ku70 and Ku80. Those two proteins are key 
proteins in non-homologue end joining, and also 
play a strong regulatory role in apoptosis through 
Bax/Bcl-2 interactions [29,30]. 
Our experimental results show that there is 
sufficient evidence to infer that the expression of  
MVP is not directly correlated with the proliferation 
of the cell. Higher percentages of high expression 
MVP in IIIA and IIIB than in IIB are probably 
related with potential metastasis and ability of 
cancer cell in preventing apoptosis as a part of 
prognosis. 
There is no correlation between MVP and 
radiation response after treatment completed. It is 
different with some reports that high expression of 
MVP will correlate with poor prognosis after 
radiotherapy [29,30]. This differing result is 
possibly due to some factors which also contribute 
to chemoradiotherapy response. Probably all 
patients included in this research were without 
hypoxic condition. Hypoxic condition was related to 
high expressions of major vault protein in cervical 
cancer treated with chemoradiotherapy [16,34]. 
This study actually has limitations, since the 
duration of observation of chemoradiotherapy 
clinical response was only three months after the 
treatment, and the response was only observed 
through pelvic control method. As high expressions 
of MVP tend to be found in higher clinical stages 
than in lower ones, we think that it will be 
influenced by the responses long time after 
treatment. It is suggested that in the next study, the 
response is observed for more than three months and 
also to use quantitative method such as computed 
tomography scan or magnetic resonance imaging. 
 
 
CONCLUSION 
 
High expressions of MVP are related to 
AgNOR degradation in S phase of cell cycle. No 
relationship was found between MVP and both of 
protein p53 and MIB-1. Expression of MVP is not 
associated with early clinical response of 
chemoradiotherapy in cervical cancer and only tends 
to be associated with the clinical stage of the patient. 
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